Exudative Macular Degeneration Clinical Trial
Official title:
Personalized Treatment Aided by Automated Analysis of Fluid in Active Neovascular Age-related Macular Degeneration (nAMD) in a Prospective, Multicenter, Randomized Study.
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
Status | Recruiting |
Enrollment | 290 |
Est. completion date | October 1, 2023 |
Est. primary completion date | October 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 100 Years |
Eligibility | Inclusion Criteria - Adults = 50 years - Active neovascular AMD (classic, occult choroidal neovascularization (CNV), RAP lesion or PCV lesion) assessed by OCT, OCTA, FA - Patients who have a BCVA score better or equal 0.1 (20/200) in the study eye using ETDRS - No significant fibrosis or geographic atrophy (GA) involving the fovea - Willingness and ability to comply with study visits and study procedures - Signed informed consent form Exclusion Criteria - Hypersensitivity to Fluoresceine, Ranibizumab, Aflibercept, Brolucizumab or to any of the excipients (Polysorbate 20, Sodium dihydrogen phosphate, monohydrate, Disodium hydrogen phosphate, heptahydrate, Sodium chloride, Sucrose) - Any surgical treatment of the eye within 3 months prior to baseline in the study eye - History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) - History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Visit 0, or a history of post-operative complications within the last 12 months preceding Visit 0 in the study eye (uveitis, cyclitis etc.) - History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) = 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio >0,9 - Aphakia in the study eye - Presence of a retinal pigment epithelial tear involving the macula in the study eye - Any concurrent intraocular condition in the study eye (e.g. advanced cataract or diabetic retinopathy) that, in the opinion of the investigator, will most likely require medical or surgical intervention during the twelve-month study period to prevent or treat visual loss that might result from that condition - Active intraocular inflammation (grade trace or above) in the study eye - Active or suspected ocular or periocular infection in the study eye - Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye - Current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment - Evidence of current infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye - Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could cause an unwanted effect on treatment efficacy, compliance or require intraocular surgery (except for cataract surgery) during the study period - Presence of corneal decompensation, haze or scaring with an impact on BCVA |
Country | Name | City | State |
---|---|---|---|
Austria | Department of Ophthalmology, Medical University of Vienna, Austria | Vienna |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of injections | Number of injections necessary within study period | 12 months | |
Secondary | Number of injections Best-corrected visual acuity (BCVA) assessed by ETDRS Score | Longitudinal changes within each group in ETDRS-BCVA and quantitative anatomic measurements in the macula assessed with noninvasive imaging | 12 months | |
Secondary | Macular fluid volumes | Changes in total amount of fluid in nanoliters within the central millimeter assessed with automated quantitative fluid measurement on noninvasive OCT imaging. | 12 months | |
Secondary | Formation of geographic-like macular atrophy | Formation of geographic-like macular atrophy assessed by fundus photography with specials filters | 12 months | |
Secondary | Formation of retinal tears | Formation of retinal tears assessed by OCT | 12 months | |
Secondary | Chorioretinal perfusion | Chorioretinal perfusion (OCTA, ICG) | 12 months | |
Secondary | Perfusion of the neovascular lesion | Perfusion of the neovascular lesion (OCTA, FA and ICG, SS) | 12 months | |
Secondary | Quality of Life by Questionnaire | Quality of Life assessed by Questionnaire NEI - VFQ 25 | 12 months | |
Secondary | Central retinal thickness | Measurement of central retinal thickness in micrometers on noninvasive OCT imaging | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01835067 -
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
|
Phase 2/Phase 3 | |
Completed |
NCT01674569 -
Pilot Study of X-82 in Patients With Wet AMD
|
Phase 1/Phase 2 | |
Recruiting |
NCT04504123 -
MMP-9 Inhibition for Recalcitrant Wet AMD
|
Phase 2 | |
Completed |
NCT01473251 -
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
|
N/A | |
Completed |
NCT01617148 -
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
|
Phase 4 | |
Completed |
NCT01535950 -
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT02287298 -
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
|
N/A | |
Active, not recruiting |
NCT03803631 -
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
|